Back close

A Molecular Receptor Targeted, Hydroxyapatite Nanocrystal based Multi-modal Contrast Agent

Publication Type : Journal Article

Thematic Areas : Nanosciences and Molecular Medicine

Publisher : Biomaterials

Source : Biomaterials, Volume 31, Number 9, p.2606-2616 (2010)

Url :

Keywords : animal cell, Animals, Apatite, article, Average size, biocompatibility, Biological organs, Biominerals, cancer cell culture, Cancer cells, Cancer targeting, Carbodiimides, Carrier Proteins, Cell culture, Cell Line, Cell Surface, Co-doping, Contrast agent, Contrast imaging, Contrast Media, contrast medium, controlled study, Crystal impurities, crystal structure, crystallography, cytotoxicity, Diagnosis, Doping (additives), Durapatite, Electronic transition, Endothelial cells, Europium, Fibroblast cells, flow cytometry, Fluorescence, fluorescence imaging, Folate receptor, folic acid, Folic acids, gadolinium, Hexagonal crystal structure, human, human cell, Human endothelial cells, Human lung cancer cell line, Humans, Hydroxyapatite, Hydroxyapatite nanocrystals, Imaging systems, In-situ, Infrared devices, Infrared Rays, Magnetic resonance, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Magnetics, Medical diagnosis, Medical imaging, Membrane receptors, Mice

Campus : Kochi

School : Center for Nanosciences

Center : Amrita Center for Nanosciences and Molecular Medicine Move, Nanosciences

Department : Nanosciences and Molecular Medicine

Year : 2010

Abstract : Multi-modal molecular imaging can significantly improve the potential of non-invasive medical diagnosis by combining basic anatomical descriptions with in-depth phenotypic characteristics of disease. Contrast agents with multifunctional properties that can sense and enhance the signature of specific molecular markers, together with high biocompatibility are essential for combinatorial molecular imaging approaches. Here, we report a multi-modal contrast agent based on hydroxyapatite nanocrystals (nHAp), which is engineered to show simultaneous contrast enhancement for three major molecular imaging techniques such as magnetic resonance imaging (MRI), X-ray imaging and near-infrared (NIR) fluorescence imaging. Monodispersed nHAp crystals of average size ∼30 nm and hexagonal crystal structure were in situ doped with multiple rare-earth impurities by a surfactant-free, aqueous wet-chemical method at 100 °C. Doping of nHAp with Eu3+ (3 at%) resulted bright near-infrared fluorescence (700 nm) due to efficient 5D0-7F4 electronic transition and co-doping with Gd3+ resulted enhanced paramagnetic longitudinal relaxivity (r1 ∼12 mM-1 s-1) suitable for T1 weighted MR imaging together with ∼80% X-ray attenuation suitable for X-ray contrast imaging. Capability of MF-nHAp to specifically target and enhance the signature of molecular receptors (folate) in cancer cells was realized by carbodiimide grafting of cell-membrane receptor ligand folic acid (FA) on MF-nHAp surface aminized with dendrigraft polymer, polyethyleneimine (PEI). The FA-PEI-MF-nHAp conjugates showed specific aggregation on FR+ve cells while leaving the negative control cells untouched. Nanotoxicity evaluation of this multifunctional nHAp carried out on primary human endothelial cells (HUVEC), normal mouse lung fibroblast cell line (L929), human nasopharyngeal carcinoma (KB) and human lung cancer cell line (A549) revealed no apparent toxicity even upto relatively higher doses of 500 μg/mL and 48 h of incubation. Flow-cytometry based reactive oxygen species (ROS) analysis also showed no significant levels of ROS generation in the nHAp treated cells. The tri-modal contrast imaging functionality together with molecular receptor targeting capability and biocompatibility makes MF-nHAp a promising biomineral contrast agent for combinatorial molecular imaging. © 2009 Elsevier Ltd. All rights reserved.

Cite this Research Publication : Anusha Ashokan, Dr. Deepthy Menon, Nair, S., and Dr. Manzoor K., “A Molecular Receptor Targeted, Hydroxyapatite Nanocrystal based Multi-modal Contrast Agent”, Biomaterials, vol. 31, pp. 2606-2616, 2010.

Admissions Apply Now